Advertisements – Advertising at The News And Times – advertising-newsandtimes.com | WE CONNECT!

Audio | Video | Top News | On Twitter | Security | FBI | Capitol Riot | JOSSICA | Trump | Russia | Putin | Russia – Ukraine War | Covid-19 | Brooklyn NY | Puerto Rico | World 

My News Links

July 5, 2022 2:30 am

The News And Times | Featured Posts | All Articles | Current News | Selected Articles | Shared Links | Opinions | In My Opinion | Sites | Blogs | Links | Twitter | Facebook

Categories
Current News

Sanofi says COVID-19 vaccine candidate yields positive trial data

Advertisements - Advertising at The News And Times - advertising-newsandtimes.com | WE CONNECT!
Spread the news

Listen to this article
2022-06-24T05:43:12Z

A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier

Sanofi’s COVID-19 vaccine candidate, which is modelled on the virus’s Beta antigen, delivered 72% efficacy in adults against the Omicron strain, the French drugmaker said on Friday, citing data gathered in a study.

Advertisements - Advertising at The News And Times - advertising-newsandtimes.com | WE CONNECT!

“Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,” the firm, which is developing the vaccine jointly with Britain’s GSK(GSK.L), said in a statement.

The new data supporting its booster vaccine will be submitted to regulatory authorities, Sanofi added, reiterating its plan to start marketing its jab later this year.


Spread the news
Advertisements - Advertising at The News And Times - advertising-newsandtimes.com | WE CONNECT!
WP Radio
WP Radio
OFFLINE LIVE